A Cost-Effectiveness Analysis of Novel Oral Anticoagulants for Primary Prevention of Venous Thromboembolic Disease

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.137
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Oral Anticoagulants for Prevention of Stroke in Atrial Fibrillation: Systematic Review, Network Meta-Analysis, and Cost Effectiveness Analysis

British Medical Journal
Medicine
2018English

Prevention and Treatment of Venous Thromboembolic Disease

Prescriber
Pharmacology
2018English

Novel Anticoagulants for Thromboembolic Complications Prevention in Nonvalvular Atrial Fibrillation

Russian Journal of Cardiology
Cardiovascular MedicineCardiology
2015English

Cost-Effectiveness of Oral Anticoagulants for Treatment of Atrial Fibrillation

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2013English

Cost-Effectiveness of New Oral Anticoagulants for Patients With Atrial Fibrillation – A Decision Analysis

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2013English

Oral Anticoagulants in the Treatment of Venous Thromboembolic Complications: Focus on Apixaban

Medical Council
2017English

Prevention and Treatment of Venous Thromboembolism With New Oral Anticoagulants: A Practical Update for Clinicians

Thrombosis
Cardiovascular MedicineHematologyCardiology
2013English

Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) for Thromboembolic Prevention, Are They Safe in Congenital Heart Disease? Results of a Worldwide Study

International Journal of Cardiology
Cardiovascular MedicineCardiology
2020English

Antithrombotic Therapy for Venous Thromboembolic Disease

Chest
CardiologyCritical CareCardiovascular MedicineIntensive Care MedicinePulmonaryRespiratory Medicine
2001English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy